MovDisordV3, PascalFrancis, Curation, bibRecord, 002314

Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease

Identifieur interne : 002314 ( PascalFrancis/Curation ); précédent : 002313; suivant : 002315

Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease

Auteurs : Elisabeth Wolf [Autriche] ; Klaus Seppi [Autriche] ; Regina Katzenschlager [Autriche] ; Guenter Hochschorner [Autriche] ; Gerhard Ransmayr [Autriche] ; Petra Schwingenschuh [Autriche] ; Erwin Ott [Autriche] ; Iris Kloiber [Autriche] ; Dietrich Haubenberger [Autriche] ; Eduard Auff [Autriche] ; Werner Poewe [Autriche]

Source :

Movement disorders [ 0885-3185 ] ; 2010.

RBID : Pascal:10-0377327

Descripteurs français

Pascal (Inist)
- Maladie de Parkinson, Dyskinésie, Pathologie du système nerveux, Long terme, Amantadine.

English descriptors

KwdEn :
- Amantadine, Dyskinesia, Long term, Nervous system diseases, Parkinson disease.

Abstract

Several randomized placebo-controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo-controlled parallel-group study was performed to assess the long-term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year- were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1-4.03) at baseline to 4.28 (95% CI, 3.1-5.4) at three-week follow-up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1-4.4) to follow-up 3.6 (95% CI, 2.3-4.8) in patients staying on amantadine. These findings argue for long-term antidyskinetic efficacy of amantadine in PD patients with LID's.

A01	`01`	`1`		`@0 0885-3185`
A03		`1`		`@0 Mov. disord.`
A05				`@2 25`
A06				`@2 10`
A08	`01`	`1`	`ENG`	`@1 Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease`
A11	`01`	`1`		`@1 WOLF (Elisabeth)`
A11	`02`	`1`		`@1 SEPPI (Klaus)`
A11	`03`	`1`		`@1 KATZENSCHLAGER (Regina)`
A11	`04`	`1`		`@1 HOCHSCHORNER (Guenter)`
A11	`05`	`1`		`@1 RANSMAYR (Gerhard)`
A11	`06`	`1`		`@1 SCHWINGENSCHUH (Petra)`
A11	`07`	`1`		`@1 OTT (Erwin)`
A11	`08`	`1`		`@1 KLOIBER (Iris)`
A11	`09`	`1`		`@1 HAUBENBERGER (Dietrich)`
A11	`10`	`1`		`@1 AUFF (Eduard)`
A11	`11`	`1`		`@1 POEWE (Werner)`
A14	`01`			`@1 Department of Neurology, Medical University Innsbruck @2 Innsbruck @3 AUT @Z 1 aut. @Z 2 aut. @Z 11 aut.`
A14	`02`			`@1 Department of Neurology, Sozialmedizinisches Zentrum Ost @2 Vienna @3 AUT @Z 3 aut.`
A14	`03`			`@1 Department of Neurology, Neurological Center Rosenhügel @2 Vienna @3 AUT @Z 4 aut.`
A14	`04`			`@1 Department of Neurology, General Hospital Linz @2 Linz @3 AUT @Z 5 aut.`
A14	`05`			`@1 Department of Neurology, Medical University Graz @2 Graz @3 AUT @Z 6 aut. @Z 7 aut.`
A14	`06`			`@1 Department of Neurology, Barmherzige Brüder Graz @2 Graz @3 AUT @Z 8 aut.`
A14	`07`			`@1 Department of Neurology, Medical University of Vienna @2 Vienna @3 AUT @Z 9 aut. @Z 10 aut.`
A20				`@1 1357-1363`
A21				`@1 2010`
A23	`01`			`@0 ENG`
A43	`01`			`@1 INIST @2 20953 @5 354000194762830050`
A44				`@0 0000 @1 © 2010 INIST-CNRS. All rights reserved.`
A45				`@0 26 ref.`
A47	`01`	`1`		`@0 10-0377327`
A60				`@1 P`
A61				`@0 A`
A64	`01`	`1`		`@0 Movement disorders`
A66	`01`			`@0 USA`
C01	`01`		`ENG`	@0 Several randomized placebo-controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo-controlled parallel-group study was performed to assess the long-term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year- were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1-4.03) at baseline to 4.28 (95% CI, 3.1-5.4) at three-week follow-up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1-4.4) to follow-up 3.6 (95% CI, 2.3-4.8) in patients staying on amantadine. These findings argue for long-term antidyskinetic efficacy of amantadine in PD patients with LID's.
C02	`01`	`X`		`@0 002B17`
C02	`02`	`X`		`@0 002B17G`
C03	`01`	`X`	`FRE`	`@0 Maladie de Parkinson @2 NM @5 01`
C03	`01`	`X`	`ENG`	`@0 Parkinson disease @2 NM @5 01`
C03	`01`	`X`	`SPA`	`@0 Parkinson enfermedad @2 NM @5 01`
C03	`02`	`X`	`FRE`	`@0 Dyskinésie @5 02`
C03	`02`	`X`	`ENG`	`@0 Dyskinesia @5 02`
C03	`02`	`X`	`SPA`	`@0 Disquinesia @5 02`
C03	`03`	`X`	`FRE`	`@0 Pathologie du système nerveux @5 03`
C03	`03`	`X`	`ENG`	`@0 Nervous system diseases @5 03`
C03	`03`	`X`	`SPA`	`@0 Sistema nervioso patología @5 03`
C03	`04`	`X`	`FRE`	`@0 Long terme @5 09`
C03	`04`	`X`	`ENG`	`@0 Long term @5 09`
C03	`04`	`X`	`SPA`	`@0 Largo plazo @5 09`
C03	`05`	`X`	`FRE`	`@0 Amantadine @2 NK @2 FR @5 10`
C03	`05`	`X`	`ENG`	`@0 Amantadine @2 NK @2 FR @5 10`
C03	`05`	`X`	`SPA`	`@0 Amantadina @2 NK @2 FR @5 10`
C07	`01`	`X`	`FRE`	`@0 Pathologie de l'encéphale @5 37`
C07	`01`	`X`	`ENG`	`@0 Cerebral disorder @5 37`
C07	`01`	`X`	`SPA`	`@0 Encéfalo patología @5 37`
C07	`02`	`X`	`FRE`	`@0 Syndrome extrapyramidal @5 38`
C07	`02`	`X`	`ENG`	`@0 Extrapyramidal syndrome @5 38`
C07	`02`	`X`	`SPA`	`@0 Extrapiramidal síndrome @5 38`
C07	`03`	`X`	`FRE`	`@0 Maladie dégénérative @5 39`
C07	`03`	`X`	`ENG`	`@0 Degenerative disease @5 39`
C07	`03`	`X`	`SPA`	`@0 Enfermedad degenerativa @5 39`
C07	`04`	`X`	`FRE`	`@0 Pathologie du système nerveux central @5 40`
C07	`04`	`X`	`ENG`	`@0 Central nervous system disease @5 40`
C07	`04`	`X`	`SPA`	`@0 Sistema nervosio central patología @5 40`
C07	`05`	`X`	`FRE`	`@0 Mouvement involontaire @5 42`
C07	`05`	`X`	`ENG`	`@0 Involuntary movement @5 42`
C07	`05`	`X`	`SPA`	`@0 Movimiento involuntario @5 42`
C07	`06`	`X`	`FRE`	`@0 Trouble neurologique @5 43`
C07	`06`	`X`	`ENG`	`@0 Neurological disorder @5 43`
C07	`06`	`X`	`SPA`	`@0 Trastorno neurológico @5 43`
N21				`@1 242`
N44	`01`			`@1 OTO`
N82				`@1 OTO`

Links toward previous steps (curation, corpus...)

to stream PascalFrancis, to step Corpus: Pour aller vers cette notice dans l'étape Curation :000A05

Links to Exploration step

Pascal:10-0377327

Le document en format XML

<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en" level="a">Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease</title>
<author><name sortKey="Wolf, Elisabeth" sort="Wolf, Elisabeth" uniqKey="Wolf E" first="Elisabeth" last="Wolf">Elisabeth Wolf</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Sozialmedizinisches Zentrum Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Hochschorner, Guenter" sort="Hochschorner, Guenter" uniqKey="Hochschorner G" first="Guenter" last="Hochschorner">Guenter Hochschorner</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Neurological Center Rosenhügel</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Ransmayr, Gerhard" sort="Ransmayr, Gerhard" uniqKey="Ransmayr G" first="Gerhard" last="Ransmayr">Gerhard Ransmayr</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, General Hospital Linz</s1>
<s2>Linz</s2>
<s3>AUT</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Schwingenschuh, Petra" sort="Schwingenschuh, Petra" uniqKey="Schwingenschuh P" first="Petra" last="Schwingenschuh">Petra Schwingenschuh</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Medical University Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Ott, Erwin" sort="Ott, Erwin" uniqKey="Ott E" first="Erwin" last="Ott">Erwin Ott</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Medical University Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Kloiber, Iris" sort="Kloiber, Iris" uniqKey="Kloiber I" first="Iris" last="Kloiber">Iris Kloiber</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Barmherzige Brüder Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Haubenberger, Dietrich" sort="Haubenberger, Dietrich" uniqKey="Haubenberger D" first="Dietrich" last="Haubenberger">Dietrich Haubenberger</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Neurology, Medical University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Auff, Eduard" sort="Auff, Eduard" uniqKey="Auff E" first="Eduard" last="Auff">Eduard Auff</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Neurology, Medical University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
</titleStmt>
<publicationStmt><idno type="wicri:source">INIST</idno>
<idno type="inist">10-0377327</idno>
<date when="2010">2010</date>
<idno type="stanalyst">PASCAL 10-0377327 INIST</idno>
<idno type="RBID">Pascal:10-0377327</idno>
<idno type="wicri:Area/PascalFrancis/Corpus">000A05</idno>
<idno type="wicri:Area/PascalFrancis/Curation">002314</idno>
</publicationStmt>
<sourceDesc><biblStruct><analytic><title xml:lang="en" level="a">Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease</title>
<author><name sortKey="Wolf, Elisabeth" sort="Wolf, Elisabeth" uniqKey="Wolf E" first="Elisabeth" last="Wolf">Elisabeth Wolf</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Seppi, Klaus" sort="Seppi, Klaus" uniqKey="Seppi K" first="Klaus" last="Seppi">Klaus Seppi</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Katzenschlager, Regina" sort="Katzenschlager, Regina" uniqKey="Katzenschlager R" first="Regina" last="Katzenschlager">Regina Katzenschlager</name>
<affiliation wicri:level="1"><inist:fA14 i1="02"><s1>Department of Neurology, Sozialmedizinisches Zentrum Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>3 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Hochschorner, Guenter" sort="Hochschorner, Guenter" uniqKey="Hochschorner G" first="Guenter" last="Hochschorner">Guenter Hochschorner</name>
<affiliation wicri:level="1"><inist:fA14 i1="03"><s1>Department of Neurology, Neurological Center Rosenhügel</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Ransmayr, Gerhard" sort="Ransmayr, Gerhard" uniqKey="Ransmayr G" first="Gerhard" last="Ransmayr">Gerhard Ransmayr</name>
<affiliation wicri:level="1"><inist:fA14 i1="04"><s1>Department of Neurology, General Hospital Linz</s1>
<s2>Linz</s2>
<s3>AUT</s3>
<sZ>5 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Schwingenschuh, Petra" sort="Schwingenschuh, Petra" uniqKey="Schwingenschuh P" first="Petra" last="Schwingenschuh">Petra Schwingenschuh</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Medical University Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Ott, Erwin" sort="Ott, Erwin" uniqKey="Ott E" first="Erwin" last="Ott">Erwin Ott</name>
<affiliation wicri:level="1"><inist:fA14 i1="05"><s1>Department of Neurology, Medical University Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Kloiber, Iris" sort="Kloiber, Iris" uniqKey="Kloiber I" first="Iris" last="Kloiber">Iris Kloiber</name>
<affiliation wicri:level="1"><inist:fA14 i1="06"><s1>Department of Neurology, Barmherzige Brüder Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Haubenberger, Dietrich" sort="Haubenberger, Dietrich" uniqKey="Haubenberger D" first="Dietrich" last="Haubenberger">Dietrich Haubenberger</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Neurology, Medical University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Auff, Eduard" sort="Auff, Eduard" uniqKey="Auff E" first="Eduard" last="Auff">Eduard Auff</name>
<affiliation wicri:level="1"><inist:fA14 i1="07"><s1>Department of Neurology, Medical University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
<author><name sortKey="Poewe, Werner" sort="Poewe, Werner" uniqKey="Poewe W" first="Werner" last="Poewe">Werner Poewe</name>
<affiliation wicri:level="1"><inist:fA14 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</inist:fA14>
<country>Autriche</country>
</affiliation>
</author>
</analytic>
<series><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
<imprint><date when="2010">2010</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
<seriesStmt><title level="j" type="main">Movement disorders</title>
<title level="j" type="abbreviated">Mov. disord.</title>
<idno type="ISSN">0885-3185</idno>
</seriesStmt>
</fileDesc>
<profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Amantadine</term>
<term>Dyskinesia</term>
<term>Long term</term>
<term>Nervous system diseases</term>
<term>Parkinson disease</term>
</keywords>
<keywords scheme="Pascal" xml:lang="fr"><term>Maladie de Parkinson</term>
<term>Dyskinésie</term>
<term>Pathologie du   système nerveux</term>
<term>Long terme</term>
<term>Amantadine</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front><div type="abstract" xml:lang="en">Several randomized placebo-controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo-controlled parallel-group study was performed to assess the long-term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year- were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1-4.03) at baseline to 4.28 (95% CI, 3.1-5.4) at three-week follow-up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1-4.4) to follow-up 3.6 (95% CI, 2.3-4.8) in patients staying on amantadine. These findings argue for long-term antidyskinetic efficacy of amantadine in PD patients with LID's.</div>
</front>
</TEI>
<inist><standard h6="B"><pA><fA01 i1="01" i2="1"><s0>0885-3185</s0>
</fA01>
<fA03 i2="1"><s0>Mov. disord.</s0>
</fA03>
<fA05><s2>25</s2>
</fA05>
<fA06><s2>10</s2>
</fA06>
<fA08 i1="01" i2="1" l="ENG"><s1>Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease</s1>
</fA08>
<fA11 i1="01" i2="1"><s1>WOLF (Elisabeth)</s1>
</fA11>
<fA11 i1="02" i2="1"><s1>SEPPI (Klaus)</s1>
</fA11>
<fA11 i1="03" i2="1"><s1>KATZENSCHLAGER (Regina)</s1>
</fA11>
<fA11 i1="04" i2="1"><s1>HOCHSCHORNER (Guenter)</s1>
</fA11>
<fA11 i1="05" i2="1"><s1>RANSMAYR (Gerhard)</s1>
</fA11>
<fA11 i1="06" i2="1"><s1>SCHWINGENSCHUH (Petra)</s1>
</fA11>
<fA11 i1="07" i2="1"><s1>OTT (Erwin)</s1>
</fA11>
<fA11 i1="08" i2="1"><s1>KLOIBER (Iris)</s1>
</fA11>
<fA11 i1="09" i2="1"><s1>HAUBENBERGER (Dietrich)</s1>
</fA11>
<fA11 i1="10" i2="1"><s1>AUFF (Eduard)</s1>
</fA11>
<fA11 i1="11" i2="1"><s1>POEWE (Werner)</s1>
</fA11>
<fA14 i1="01"><s1>Department of Neurology, Medical University Innsbruck</s1>
<s2>Innsbruck</s2>
<s3>AUT</s3>
<sZ>1 aut.</sZ>
<sZ>2 aut.</sZ>
<sZ>11 aut.</sZ>
</fA14>
<fA14 i1="02"><s1>Department of Neurology, Sozialmedizinisches Zentrum Ost</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>3 aut.</sZ>
</fA14>
<fA14 i1="03"><s1>Department of Neurology, Neurological Center Rosenhügel</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>4 aut.</sZ>
</fA14>
<fA14 i1="04"><s1>Department of Neurology, General Hospital Linz</s1>
<s2>Linz</s2>
<s3>AUT</s3>
<sZ>5 aut.</sZ>
</fA14>
<fA14 i1="05"><s1>Department of Neurology, Medical University Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>6 aut.</sZ>
<sZ>7 aut.</sZ>
</fA14>
<fA14 i1="06"><s1>Department of Neurology, Barmherzige Brüder Graz</s1>
<s2>Graz</s2>
<s3>AUT</s3>
<sZ>8 aut.</sZ>
</fA14>
<fA14 i1="07"><s1>Department of Neurology, Medical University of Vienna</s1>
<s2>Vienna</s2>
<s3>AUT</s3>
<sZ>9 aut.</sZ>
<sZ>10 aut.</sZ>
</fA14>
<fA20><s1>1357-1363</s1>
</fA20>
<fA21><s1>2010</s1>
</fA21>
<fA23 i1="01"><s0>ENG</s0>
</fA23>
<fA43 i1="01"><s1>INIST</s1>
<s2>20953</s2>
<s5>354000194762830050</s5>
</fA43>
<fA44><s0>0000</s0>
<s1>© 2010 INIST-CNRS. All rights reserved.</s1>
</fA44>
<fA45><s0>26 ref.</s0>
</fA45>
<fA47 i1="01" i2="1"><s0>10-0377327</s0>
</fA47>
<fA60><s1>P</s1>
</fA60>
<fA61><s0>A</s0>
</fA61>
<fA64 i1="01" i2="1"><s0>Movement disorders</s0>
</fA64>
<fA66 i1="01"><s0>USA</s0>
</fA66>
<fC01 i1="01" l="ENG"><s0>Several randomized placebo-controlled trials have consistently shown antidyskinetic effects of amantadine in levodopa treated patients with advanced Parkinson's disease (PD). However, all of these were of short duration and there have been claims that the effect of amantadine on levodopa induced dyskinesias (LID's) wear off after about 9 months of treatment. This randomized placebo-controlled parallel-group study was performed to assess the long-term antidyskinetic effect of amantadine in 32 PD patients, who after having been on stable amantadine therapy for LID over at least one year- were switched in a double blind manner to amantadine or placebo and followed for 3 weeks. Dyskinesia duration and intensity were assessed by UPDRS IV items 32 and 33 as well as by patient's diaries. The primary outcome was the score change of UPDRS IV items 32 + 33 between baseline and 3 weeks after treatment as well as the between treatment group comparison of the score change of UPDRS IV items 32 + 33. There was a significant increase of UPDRS IV items 32 + 33 in patients treated with placebo from 3.06 (95% CI, 2.1-4.03) at baseline to 4.28 (95% CI, 3.1-5.4) at three-week follow-up (P = 0.02) compared with no significant change between baseline 3.2 (95% CI, 2.1-4.4) to follow-up 3.6 (95% CI, 2.3-4.8) in patients staying on amantadine. These findings argue for long-term antidyskinetic efficacy of amantadine in PD patients with LID's.</s0>
</fC01>
<fC02 i1="01" i2="X"><s0>002B17</s0>
</fC02>
<fC02 i1="02" i2="X"><s0>002B17G</s0>
</fC02>
<fC03 i1="01" i2="X" l="FRE"><s0>Maladie de Parkinson</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="ENG"><s0>Parkinson disease</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="01" i2="X" l="SPA"><s0>Parkinson enfermedad</s0>
<s2>NM</s2>
<s5>01</s5>
</fC03>
<fC03 i1="02" i2="X" l="FRE"><s0>Dyskinésie</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="ENG"><s0>Dyskinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="02" i2="X" l="SPA"><s0>Disquinesia</s0>
<s5>02</s5>
</fC03>
<fC03 i1="03" i2="X" l="FRE"><s0>Pathologie du   système nerveux</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="ENG"><s0>Nervous system diseases</s0>
<s5>03</s5>
</fC03>
<fC03 i1="03" i2="X" l="SPA"><s0>Sistema nervioso patología</s0>
<s5>03</s5>
</fC03>
<fC03 i1="04" i2="X" l="FRE"><s0>Long terme</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="ENG"><s0>Long term</s0>
<s5>09</s5>
</fC03>
<fC03 i1="04" i2="X" l="SPA"><s0>Largo plazo</s0>
<s5>09</s5>
</fC03>
<fC03 i1="05" i2="X" l="FRE"><s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="ENG"><s0>Amantadine</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC03 i1="05" i2="X" l="SPA"><s0>Amantadina</s0>
<s2>NK</s2>
<s2>FR</s2>
<s5>10</s5>
</fC03>
<fC07 i1="01" i2="X" l="FRE"><s0>Pathologie de l'encéphale</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="ENG"><s0>Cerebral disorder</s0>
<s5>37</s5>
</fC07>
<fC07 i1="01" i2="X" l="SPA"><s0>Encéfalo patología</s0>
<s5>37</s5>
</fC07>
<fC07 i1="02" i2="X" l="FRE"><s0>Syndrome extrapyramidal</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="ENG"><s0>Extrapyramidal syndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="02" i2="X" l="SPA"><s0>Extrapiramidal síndrome</s0>
<s5>38</s5>
</fC07>
<fC07 i1="03" i2="X" l="FRE"><s0>Maladie dégénérative</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="ENG"><s0>Degenerative disease</s0>
<s5>39</s5>
</fC07>
<fC07 i1="03" i2="X" l="SPA"><s0>Enfermedad degenerativa</s0>
<s5>39</s5>
</fC07>
<fC07 i1="04" i2="X" l="FRE"><s0>Pathologie du   système nerveux central</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="ENG"><s0>Central nervous system disease</s0>
<s5>40</s5>
</fC07>
<fC07 i1="04" i2="X" l="SPA"><s0>Sistema nervosio central patología</s0>
<s5>40</s5>
</fC07>
<fC07 i1="05" i2="X" l="FRE"><s0>Mouvement involontaire</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="ENG"><s0>Involuntary movement</s0>
<s5>42</s5>
</fC07>
<fC07 i1="05" i2="X" l="SPA"><s0>Movimiento involuntario</s0>
<s5>42</s5>
</fC07>
<fC07 i1="06" i2="X" l="FRE"><s0>Trouble neurologique</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="ENG"><s0>Neurological disorder</s0>
<s5>43</s5>
</fC07>
<fC07 i1="06" i2="X" l="SPA"><s0>Trastorno neurológico</s0>
<s5>43</s5>
</fC07>
<fN21><s1>242</s1>
</fN21>
<fN44 i1="01"><s1>OTO</s1>
</fN44>
<fN82><s1>OTO</s1>
</fN82>
</pA>
</standard>
</inist>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/PascalFrancis/Curation

HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002314 | SxmlIndent | more

HfdSelect -h $EXPLOR_AREA/Data/PascalFrancis/Curation/biblio.hfd -nk 002314 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    PascalFrancis
   |étape=   Curation
   |type=    RBID
   |clé=     Pascal:10-0377327
   |texte=   Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease
}}

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024

	Movement Disorders (revue)
	Attention, ce site est en cours de développement ! Attention, site généré par des moyens informatiques à partir de corpus bruts. Les informations ne sont donc pas validées.

Movement Disorders (revue)

Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease

Long-Term Antidyskinetic Efficacy of Amantadine in Parkinson's Disease

Source :

Descripteurs français

English descriptors

Abstract

Links toward previous steps (curation, corpus...)

Links to Exploration step

Le document en format XML

Pour manipuler ce document sous Unix (Dilib)

Pour mettre un lien sur cette page dans le réseau Wicri